**Supplementary Table 3. Baseline characteristics of patients with ACE2 levels in the prospective research cohort**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Control - no PPI** | **Control - PPI** | **COVID - no PPI** | **COVID - PPI** |
|  | **N=9** | **N=13** | **N=28** | **N=17**  |
|  |  |  |  |  |
| Age (years) | 58 ± 8 | 53 ± 11 | 57 ± 18 | 64 ± 9 |
| Female | 3 (33%) | 10 (77%) | 9 (32%) | 11 (65%) |
| Race |  |  |  |  |
| *Black* | 5 (56%) | 7 (58%) | 21 (81%) | 8 (47%)  |
| *Caucasian* | 4 (44%) | 5 (42%) | 3 (12%) | 7 (41%)  |
| *Other* | 0 (0%) | 1 (8%) | 2 (8 %) | 2 (12%)  |
| BMI | 32.6 ± 6.5 | 37.1 ± 8.6 | 33.0 ± 11.5 | 35.3 ± 11.0 |
| H2RA use | 0 (0%) | 2 (17%) | 0 (0%) | 3 (18%) |

PPI=proton pump inhibitor, BMI=body mass index, H2RA=histamine H2-receptor antagonists